References
- BassanR, RossiG, PoglianiEM, Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010;28:3644–3652.
- FieldingAK, BuckG, LazarusHM, Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukaemia; final results of the UKALLXII/ECOG2993 trial. Blood 2010;116(Suppl. 1): Abstract 169.
- PfeiferH, GoekbugetN, VolpC, Long-term outcome of 335 adult patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood 2010;116(Suppl. 1): Abstract 173.
- RousselotP, CayuelaJM, HayetteS, Dasatinib (Sprycel(R)) and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): kinetic of response, resistance and prognostic significance. Blood 2010;116(Suppl. 1): Abstract 172.
- JabbourE, ThomasD, CortesJ, KantarjianHM, O'BrienS. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 2010;116:2290–2300.
- PatelSB, GojoI, TidwellML, SausvilleEA, BaerMR. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma 2011;52:In press.
- GokbugetN, HartogCM, BassanR, Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 2011;96:238–244.
- PorkkaK, KoskenvesaP, LundanT, Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005–1012.